Research Square
December 1, 2025
Albert Buchard, Federico Seragnoli, Michel Sabé et al.
preprint
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with baseline depression and anxiety. This study characterized EMS in 192 adults and longitudinally followed 74 patients receiving psilocybin- or LSD-assisted therapy. We found that baseline schema burden, particularly related to failure and defectiveness,...
medRxiv
November 17, 2025
Georgia Ioakimidis-Macdougall, John Gardner, Paul Liknaitzky
preprint
Abstract First-hand experience with psychedelics may help clinicians develop skills and knowledge needed to work with the profound changes to conscious awareness occasioned by psychedelics. However, the topic remains contentious and underexplored. In this world-first study, we investigated the utility of psilocybin experiential therapist training in a sample of 14 mental healthcare...
November 16, 2025
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Journal of Humanistic Psychology
November 10, 2025
Robin J Murphy, Mia Wardlaw, Thomas A. Smith et al.
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have been published regarding the experiences of microdosers, but never in the context of a randomised controlled trial. Semi-structured video interviews with 40 healthy males were conducted following a double-blind placebo-controlled trial of 10 µg of...
Psychedelics.
October 28, 2025
James J Gattuso, Bilgenur Bezcioglu, Carey Wilson et al.
1 citation
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behaviours with attention to translational...
University of Southern Denmark Research Portal (University of Southern Denmark)
September 9, 2025
Jacob Cohen
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD) og social angstlidelse (SAD), er meget udbredte og reagerer ofte dårligt på konventionel farmakologisk behandling og psykoterapi. Nyere kliniske forsøg har vist, at psykedeliske stoffer og ketamin kan udøve hurtige og vedvarende effekter gennem...
Acta Neuropsychiatrica
September 3, 2025
Filipe Reis Teodoro Andrade, Tobias Buchborn, Gabriel Thalheimer et al.
3 citations
Abstract Background: Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression. It primarily acts through the serotonin 5-HT2A receptor but interacts with 5-HT1A and 5-HT2C receptors....
General Hospital Psychiatry
August 12, 2025
Margaret Ross, Ravi Iyer, M.l. Williams et al.
13 citations
Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.
Frontiers in Psychiatry
August 6, 2025
Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell et al.
3 citations
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological...
Frontiers in Psychiatry
August 4, 2025
Wierzbicka Małgorzata, Renata Kopczyk, Alexander L. Gerlach et al.
1 citation
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgical interventions with disfiguring...